Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 144

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 144
---
 team with respect thereto. The committee members were selected based on their knowledge of, and experience with, strategic transactions, experience in evaluating the
prospects and relative value of potential strategic partners, operational and executive experience relative to the required diligence of potential strategic partners, diversity of professional experience, and ability to meet the time commitments of
service on such committee. Aadi’s board of directors delegated to the Strategic Transaction Committee the primary authority to review and evaluate proposals for potential acquisition and in-licensing
opportunities and similar strategic opportunities, to review and evaluate the prospects for strategic partners, to interface with Aadi’s advisers and management team, and to act on behalf of Aadi’s board of directors in facilitating the
review, analysis, evaluation, monitoring and exercise of general oversight of all proceedings and activities related to any strategic transaction proposal. The Strategic Transaction Committee was not delegated the authority to approve any particular
transaction, but was directed to provide recommendations to Aadi’s board of directors with respect to various proposals and/or strategic partners. From March 22, 2024 through August 26, 2024, the Strategic Transaction Committee held
nine meetings with Aadi’s management team and its advisers to discuss, among other things, potential strategic opportunities, the asset screening process, due diligence considerations, and the retention of potential investment banks and
business development partners to assist in business development efforts.

On May 11, 2024, following authorization from Aadi’s board of
directors and based upon a recommendation from the Strategic Transaction Committee after a review of various alternatives, Aadi signed an engagement letter with Leerink Partners to serve as its financial advisor in connection with Aadi’s
comprehensive assessment of strategic options, including those related to acquisition or in-licensing opportunities.

On June 13, 2024, Aadi engaged a business development consultant with expertise in ADC and bi-specific programs
under development in China. The consultant introduced Aadi to the ADC portfolio of WuXi Biologics. In order to discuss and evaluate a possible transaction, Aadi entered into a confidentiality agreement with WuXi

- 98 -

Biologics on June 19, 2024. Aadi’s initial focus was on the Seizure Related 6 Homolog (SEZ6) ADC asset, followed by later interest in the Protein Tyrosine Kinase 7 (PTK7) CPT113 ADC and
Mucin-16 (MUC16) ADC assets amongst other programs. Following an